Impedimed Ltd (ASX:IPD)
A$ 0.053 0 (0%) Market Cap: 107.22 Mil Enterprise Value: 83.73 Mil PE Ratio: 0 PB Ratio: 2.65 GF Score: 0/100

ImpediMed Ltd NCCN Investor Update Conference Call Transcript

Mar 28, 2023 / 10:30PM GMT
Release Date Price: A$0.125
Operator

Thank you for standing by. Welcome to the ImpediMed Limited conference call. (Operator Instructions) I would now like to hand the conference over to Mr. Rick Valencia, Managing Director and CEO. Please go ahead.

Richard P. Valencia
ImpediMed Limited - MD, CEO & Director

Thank you, Rachel. Welcome, everyone, and thank you for joining us today. We're hosting this conference call to discuss our recent announcement related to the NCCN Survivorship guidelines being updated to recommend regular screening for lymphoedema, including the bioimpedance spectroscopy, commonly referred to as BIS.

Joining me on the call today is Tim Cruickshank, Chief Financial Officer; and Frank Vicini. Dr. Vicini is an internationally recognized radiation oncologist. He has extensive experience in cancer clinical trial design and implementation. He is the former Chief Medical Officer of ImpediMed from 2014 to 2022 and remains a dear friend and adviser to the company. Dr. Vicini is currently the Global Chair of Breast Cancer Research and National Director of Breast Cancer Care

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot